QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foster, A. C. Articles by Kemp, J. A. Search for Related Content PubMed PubMed Citation Articles by Foster, A. C. Articles by Kemp, J. A.

 Previous Article  |  Next Article 

Journal of Neuroscience, Vol 9, 2191-2196, Copyright © 1989 by Society for Neuroscience

ARTICLE

HA-966 antagonizes N-methyl-D-aspartate receptors through a selective interaction with the glycine modulatory site

AC Foster and JA Kemp
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, England.

3-Amino-1-hydroxypyrrolid-2-one (HA-966) has been known for several years as an excitatory amino acid antagonist, acting principally at the N-methyl-D-aspartate (NMDA) receptor subtype. We report here that HA- 966 blocks NMDA responses through a selective interaction with the glycine modulatory site present within the receptor complex. In radioligand binding experiments, HA-966 inhibited strychnine- insensitive 3H-glycine binding to rat cerebral cortex synaptic plasma membranes with an IC50 of 17.5 microM. At concentrations up to 1 mM, HA- 966 caused minimal inhibition of radioligand binding to the transmitter recognition sites of the NMDA, quisqualate, or kainate receptor subtypes and was similarly inactive against the binding of 3H- strychnine to rat spinal cord/brain stem membranes. In electrophysiological experiments, HA-966 produced a selective block of NMDA responses in a rat cortical slice preparation. The degree of antagonism caused by HA-966 was maximal at 250 microM and was not increased further by raising the HA-966 concentration. Both glycine (1 mM) and D-serine (100 microM) reversed the antagonism of NMDA responses caused by HA-966. In patch-clamp experiments using rat cortical neurons in culture, HA-966 blocked the potentiation of NMDA responses by glycine but had little effect on basal NMDA responses themselves. This profile of antagonism differs from that observed with 7- chlorokynurenate, another recently discovered antagonist of the glycine site on the NMDA receptor (Kemp et al., 1988) and may indicate that glycine antagonists of differing efficacies can exist. Previous experiments with HA-966 may now be interpreted to suggest that activation of the glycine site on the NMDA receptor occurs in vivo and is important for the participation of NMDA receptors in synaptic transmission.

This article has been cited by other articles:

				L. Chen, M. Muhlhauser, and C. R. Yang Glycine Tranporter-1 Blockade Potentiates NMDA-Mediated Responses in Rat Prefrontal Cortical Neurons In Vitro and In Vivo J Neurophysiol, February 1, 2003; 89(2): 691 - 703. [Abstract] [Full Text] [PDF]

				R. M. Allen and L. A. Dykstra N-Methyl-D-Aspartate Receptor Antagonists Potentiate the Antinociceptive Effects of Morphine in Squirrel Monkeys J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 288 - 297. [Abstract] [Full Text]

				W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]

				E. Viu, A. Zapata, J. L. Capdevila, L. H. Fossom, P. Skolnick, and R. Trullas Glycine Site Antagonists and Partial Agonists Inhibit N-Methyl-D-aspartate Receptor-Mediated [3H]Arachidonic Acid Release in Cerebellar Granule Cells J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 527 - 532. [Abstract] [Full Text]

				B. A. Morrow, E. J. K. Lee, J. R. Taylor, J. D. Elsworth, H. E. Nye, and R. H. Roth (S)-(-)-HA-966, a gamma -Hydroxybutyrate-Like Agent, Prevents Enhanced Mesocorticolimbic Dopamine Metabolism and Behavioral Correlates of Restraint Stress, Conditioned Fear and Cocaine Sensitization J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 712 - 721. [Abstract] [Full Text]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help